Every intervention Outliyr has scored for heart health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for heart health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
73 of 120 evaluated interventions score 3.0+ out of 10 for heart health · 27 comparisons
Taurine earns 9.0/10 for cardiovascular because Guan 2020 reports Confirmed meta-analysis on obesity, BP, and lipid outcomes; supports cardiometabolic breadth. Tzang 2024 points in the same direction, but route, dose, baseline status,…
Read the Taurine report →The Norwegian 4x4 receives an 8.5/10 score for the cardiovascular use case, a rating supported by the VO2peak gains and favorable cardiac remodeling reported in Wisloff 2007. The Norwegian 4x4 protocol combines…
Read the Norwegian 4×4 report →Zone 2 Cardio earns 8.5/10 for cardiovascular because Lang 2024 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Cardiorespiratory fitness is one of the…
Read the Zone 2 Cardio report →Cardiovascular benefit is the strongest case for traditional sauna, earning 8.5/10. In the KIHD cohort, Laukkanen 2015 found 4 to 7 weekly sessions associated with a fatal cardiovascular disease hazard ratio of…
Read the Traditional Sauna (Finnish Dry-Heat) report →Infrared Sauna earns 8.3/10 for cardiovascular because Hamaya 2025 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Waon therapy clinical data support cardiovascular benefit…
Read the Infrared Sauna report →Evidence puts HRV Biofeedback at 8.0/10 for cardiovascular, mainly through Rosendo da Cunha e Silva et al. 2026. Slow-breathing meta-analyses support clinically meaningful systolic blood-pressure reduction in nonclinical populations per the broader…
Read the HRV Biofeedback report →Magnesium cardiovascular earns 8.0/10 because Argeros 2025 anchors the most relevant signal. Magnesium fits cardiovascular when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score…
Read the Magnesium report →Cardiovascular scoring lands at 8.0/10 because Lincoff 2023 reported 20% lower 3-point MACE in adults with overweight or obesity and established CVD without diabetes. That makes Semaglutide more than a weight-loss drug…
Read the Semaglutide report →Cardiovascular is the strongest polyphenol use case at 7.8/10. Sesso 2022, the COSMOS RCT in 21,442 older adults, found a cocoa-flavanol supplement (500 mg/day) cut cardiovascular death 27 percent (HR 0.73) over…
Read the Polyphenols (Dietary) report →Spermidine earns 7.8/10 for cardiovascular because Kiechl 2018 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: this verified source supports cardiac autophagy and diastolic-function…
Read the Spermidine report →The cardiovascular use case for Tirzepatide receives a score of 7.8/10, reflecting the data reported in Packer et al. 2025. Tirzepatide shows promise for heart-failure with preserved ejection fraction in obese patients,…
Read the Tirzepatide report →Cardiovascular is CoQ10's strongest case at 7.5/10 because the evidence reaches hard outcomes, not just biomarkers. In chronic heart failure, Mortensen 2014 (Q-SYMBIO, n=420) found 300 mg/day cut major adverse cardiac events…
Read the Coenzyme Q10 (CoQ10 / Ubiquinol) report →Spirulina earns 7.5/10 for cardiovascular because the blood-pressure signal is real and replicated. Machowiec 2021 pooled 5 randomized trials in 230 subjects and found systolic pressure falling 4.59 mmHg and diastolic falling…
Read the Spirulina report →The strongest cardiovascular argument for Molecular Hydrogen is 7.2/10 because Jamialahmadi 2024 reports 7 trials; reported reductions in total cholesterol, triglycerides, and LDL, with no significant HDL change. Ye 2026 points in…
Read the Molecular Hydrogen report →Cardiovascular use is one of Metformin's better-supported non-glucose angles, earning 7.2/10 because UKPDS reported lower myocardial infarction and all-cause mortality in overweight patients with newly diagnosed type 2 diabetes UK Prospective Diabetes…
Read the Metformin report →The cardiovascular case scores 7.0 because rucking is built on walking, the movement with the strongest population mortality data. A 15-cohort meta-analysis of 47,471 adults found the highest step quartile had a…
Read the Rucking (Weighted Walking) report →Cardiovascular fitness scores 7.0/10. Weston 2014 found interval training raised VO2peak about 3 mL/kg/min more than moderate continuous training in cardiometabolic-disease patients, roughly double the improvement. Under medical supervision, even high-intensity work…
Read the Sprinting (Sprint Interval Training) report →Berberine earns 6.8/10 for cardiovascular; this is a targeted fit score. LDL-C, triglycerides, and total cholesterol improve in dyslipidemic adults in Koppen 2017 and Blais 2023. The PCSK9, NPC1L1, and bile-acid mechanisms…
Read the Berberine report →Blood-Flow Restriction Training reaches 6.5/10 for cardiovascular when the goal matches the population in Zeng et al. 2025. Systemic reviews such as Miller 2021 describe vascular and cardiovascular effects, but the hemodynamic…
Read the Blood-Flow Restriction Training report →Astaxanthin is a 6.5/10 cardiovascular fit because Laurindo 2025 reports 8 randomized controlled studies; 312 randomized participants by included-study table; triglycerides and HDL-C improved; LDL-C and total cholesterol were not significant; certainty…
Read the Astaxanthin report →BPC-157 cardiovascular earns 6.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits cardiovascular when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly…
Read the BPC-157 report →The cardiovascular score is 6.5/10, and TB-500 (Thymosin Beta-4 Fragment) needs careful framing. Cardiac repair evidence is mostly preclinical. Bock-Marquette 2004 showed improved cardiac function after coronary ligation in mice, while Zhou…
Read the TB-500 (Thymosin Beta-4 Fragment) report →Rapamycin cardiovascular earns 6.5/10 because Harrison 2009 anchors the most relevant signal. Rapamycin fits cardiovascular when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded…
Read the Rapamycin report →Cardiovascular is ergothioneine's strongest case at 6.5/10 because the observational signal is unusually consistent. Smith 2020 followed 3,236 adults for a median 21.4 years and found each 1 SD higher plasma ergothioneine…
Read the Ergothioneine report →Cardiovascular is chlorella's best-evidenced use case at 6.5/10 because Fallah 2018 pooled 19 RCTs (n=797) and found total cholesterol down 9.09 mg/dL, LDL down 8.32 mg/dL, and systolic blood pressure down 4.51…
Read the Chlorella report →Senolytics reaches 6.2/10 for cardiovascular when the goal matches the population in Chaib et al. 2022. Senescent endothelial-cell clearance supports vascular function in preclinical models; human cardiovascular outcome data for F+Q is…
Read the Senolytics report →Resveratrol's most credible signal is cardiovascular-risk support rather than broad prevention. Tomé-Carneiro 2012 reported inflammatory and fibrinolytic improvements with a grape nutraceutical in primary CVD prevention, but this corpus has product and…
Read the Resveratrol report →Electrolytes earns 6.0/10 for cardiovascular because Borra 2025 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Potassium intake improves blood pressure and cardiovascular risk…
Read the Electrolytes report →Vitamin D3 + K2 cardiovascular earns 6.0/10 because Knapen 2015 anchors the most relevant signal. Vitamin D3 + K2 fits cardiovascular when deficiency, bone risk, immune seasonality, or fat-soluble nutrient gaps are…
Read the Vitamin D3 + K2 report →Vitamin C scores 6.0/10 for cardiovascular support. The Juraschek 2012 meta-analysis of 29 randomized trials (median dose 500 mg/day, median 8 weeks) found a pooled systolic reduction of 3.84 mmHg, rising to…
Read the Vitamin C (Ascorbic Acid) report →For cardiovascular, Omega-3 earns 6.0/10 because the evidence points to a plausible use case without proving a universal response. Abuknesha et al. 2025 is the best anchor here because it reports 34…
Read the Omega-3 report →The practical cardiovascular read is 6.0/10 for Tesamorelin, with Falutz et al. 2010 setting the ceiling. Tesamorelin improves some cardiometabolic risk surrogates through VAT reduction, triglyceride changes, inflammatory-marker shifts, and possibly carotid…
Read the Tesamorelin report →The most interesting therapeutic-adjacent signal. Nielsen 2019 gave acute 3-hydroxybutyrate to 16 chronic heart-failure patients and saw cardiac output rise about 2.0 L per minute with an 8-point bump in ejection fraction,…
Read the Exogenous Ketones report →On cardiovascular, Retatrutide deserves 6.0/10 because Rosenstock 2023 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Weight, blood pressure, triglyceride, glucose, and inflammation markers likely move…
Read the Retatrutide report →Glycine cardiovascular earns 5.8/10 because Soh 2024 anchors the most relevant signal. Glycine fits cardiovascular because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The…
Read the Glycine report →The main limitation behind Time-Restricted Eating's 5.8/10 cardiovascular score is that the evidence points to a plausible use case without proving a universal response. Liu D et al. 2022 is the best…
Read the Time-Restricted Eating report →Quercetin lowers systolic BP by about 3.04 mmHg and diastolic BP by about 2.63 mmHg in the Serban 2016 meta-analysis of 7 RCTs (n=587), with effects strongest at doses 500 mg/day or…
Read the Quercetin report →The cardiovascular case for Essential Amino Acids is 5.5/10 because Solerte 2008 reports Personally verified PMID; sarcopenia crossover study reporting lean-mass gains with amino acid supplementation. The score stays conditional because Essential…
Read the Essential Amino Acids report →A 2024 meta-analysis notes that Whole-Body Vibration produces acute heart-rate and blood-pressure spikes comparable to light-intensity exercise Wang 2024. The Whole-Body Vibration cardiovascular use case receives a score of 5.5/10, reflecting modest…
Read the Whole-Body Vibration report →Cardiovascular use earns 5.5 out of 10. The single isolated-fucoidan human RCT, Hernandez-Corona 2014, gave 500 mg per day to 25 overweight adults for three months and found lower diastolic blood pressure…
Read the Fucoidan (Brown Seaweed Polysaccharide) report →The cardiovascular case for SS-31 (Elamipretide) lands at 5.5/10 because the evidence points to a plausible use case without proving a universal response. Zhao C et al. 2026 is the best anchor…
Read the SS-31 (Elamipretide) report →Marine plasma earns 5.5/10 for cardiovascular because the nearest human signal is a deep-sea-water proxy, not the branded product. Ham 2020 ran a double-blind crossover RCT in 37 prediabetic adults using magnesium-rich…
Read the Quinton Marine Plasma (Seawater Minerals) report →Current preclinical data give SLU-PP-332 a cardiovascular use-case score of 5.5/10, based on mouse pressure-overload heart-failure improvements reported by Xu 2024. The study showed that SLU-PP-332 enhanced ejection fraction, reduced fibrosis, and…
Read the SLU-PP-332 report →The cardiovascular case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.2/10 because Filip 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Mechanism is mostly neutral, while calcium…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →The cardiovascular score for Earthing is 5.0 / 10, based on the limited data reported in Chevalier 2012. Earthing's cardiovascular use case rests on a handful of small, unblinded or narrative studies…
Read the Earthing report →NR (Nicotinamide Riboside) earns 5.0/10 for cardiovascular because Conze 2019 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: this verified source found directional blood-pressure…
Read the NR (Nicotinamide Riboside) report →Cardiovascular evidence is reassuring but not yet a finished story. In its largest safety study the drug was noninferior to insulin glargine for major cardiovascular events, with a hazard ratio of 0.84,…
Read the Orforglipron (Foundayo) report →Mechanistically, TRT (Testosterone Replacement Therapy) fits cardiovascular at 5.0/10 because Lincoff 2023 reports TRAVERSE cardiovascular outcomes trial in 5,246 hypogonadal men with cardiovascular risk; major cardiovascular events non-inferior, with monitoring-relevant safety signals.…
Read the TRT (Testosterone Replacement Therapy) report →Cardiovascular evidence is observational and indirect rather than RCT-anchored. Higher cruciferous vegetable intake is associated with lower stroke and cardiovascular mortality in cohort work (Joshipura 1999, Zhang 2011), and air pollution detox…
Read the Sulforaphane report →HBOT has vascular and angiogenic mechanisms with small evidence in peripheral ischemia and erectile function. It is not a general cardiovascular prevention tool. Hadanny 2018 supports vascular endothelial effects in selected patients…
Read the Hyperbaric Oxygen Therapy report →Cardiovascular benefit is inferred from the inflammation and glycemic effects rather than from hard endpoint data. There are no large trials showing curcumin reduces heart attacks or strokes. The lipid data is…
Read the Curcumin report →The cardiovascular score is unchanged because fibrinogen, antioxidant, and fibrosis pathways are relevant but indirect. Pickart 2014 discusses fibrinogen and tissue-repair genes, but no human cardiovascular endpoint trial supports risk reduction.
Read the GHK-Cu report →Cardiac repair has strong preclinical and mechanistic groundwork through the Bock-Marquette and Smart series showing Tβ4 activates integrin-linked kinase and mobilizes epicardial progenitors, per Bock-Marquette 2004, but the only RGN-352 Phase 2…
Read the Thymosin Beta-4 (Tβ4) report →Cardiovascular scores 4.5/10. Kumar 2023 reported lower systolic blood pressure and improved endothelial function in older adults, and the pilot noted reduced endothelial dysfunction, but these are small trials without cardiovascular event…
Read the GlyNAC (Glycine + N-Acetylcysteine) report →Cardiovascular benefit is plausible but unproven for CagriSema specifically. Weight loss of this magnitude usually improves blood pressure and lipids, and the GLP-1 class has positive cardiovascular outcomes data from related drugs.…
Read the CagriSema (Cagrilintide + Semaglutide) report →Preserved v0.x score. Cardiovascular prevention is a poor benefit-risk fit because systemic blood routes create the most important cardiovascular safety issue: gas embolism and paradoxical embolism risk. Marchetti and La Monaca 2000…
Read the Ozone Therapy report →Zhang 2025 supports modest blood-pressure and lipid-marker improvements in metabolic syndrome-related populations, but there are no hard cardiovascular outcome trials.
Read the Saffron report →Acute blood-pressure reduction under stress is plausible from stress-challenge work, but this is not a standalone cardiovascular intervention.
Read the L-Theanine report →Cardiovascular relevance is mostly secondary to sepsis and critical illness outcomes. Wu 2013 tracked severe sepsis outcomes, but no primary cardiovascular prevention or treatment indication is established.
Read the Thymosin Alpha-1 report →Cardiovascular response is mixed: triglycerides and HDL often improve, while LDL-C and ApoB can rise meaningfully in responders. Buren 2021 found LDL-C increased in healthy young normal-weight women after ketogenic LCHF feeding,…
Read the Ketogenic Diet report →Preclinical vascular data from de Picciotto 2016 support vascular-aging mechanisms, and Zhang 2026 found a small diastolic blood-pressure signal. No cardiovascular-event RCT exists.
Read the NMN (Nicotinamide Mononucleotide) report →Reishi metabolic-syndrome RCT (Klupp 2016) found no blood pressure or lipid benefit; cordyceps cardiovascular data are preclinical. Mechanistic plausibility without human outcomes.
Read the Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) report →Steffen 2026 (Steffen 2026) found modest observational blood-pressure and hypertension associations in CARDIA and ARIC but no incident cardiovascular-disease association and no Mendelian-randomization support for causality. Sun 2025 supports biomarker-level interest in…
Read the C15 (Pentadecanoic Acid) report →Acute sessions increase cardiovascular work, and improved muscle mass may support vascular health. The evidence is not strong enough to position WB-EMS as a cardiovascular treatment or replacement for aerobic training.
Read the Full-Body EMS report →Cardiovascular benefit is indirect and modest. Stress, cortisol, sleep, inflammation, and blood-pressure endpoints can move in favorable directions in some trials, including Salve 2019. Ashwagandha is not a primary cardiovascular therapy, and…
Read the Ashwagandha report →Short-term standardized-extract trials generally do not show major liver, kidney, or lipid shifts, but there is no cardiovascular endpoint evidence. Estradiol can rise through aromatization in susceptible men.
Read the Tongkat Ali report →No proven cardiovascular benefit yet, and a heart-rate flag. A blood-pressure post-hoc was favorable, but a dedicated outcomes trial has not reported.
Read the Survodutide (BI 456906) report →Limited direct cardiovascular evidence. Antioxidant and anti-inflammatory mechanisms may support vascular health, but no human cardiovascular RCT has tested shilajit as the primary intervention.
Read the Shilajit report →AMPK activation has cardioprotective downstream effects, but MOTS-c has no direct cardiovascular RCT. The cardiovascular score stays low because support is indirect, mostly from metabolic pathway reasoning and diabetic animal models rather…
Read the MOTS-c report →Indirect mitochondrial and anti-inflammatory pathway only. Hodzic Kuerec 2024 found no clear cardiovascular outcome effect across the small human study base.
Read the Urolithin A report →Endothelial and lipid effects appear indirectly through precursor trials, not glutathione supplementation, so the direct cardiovascular case is thin at 3.0/10.
Read the Glutathione (GSH) report →No human cardiovascular outcome data; composition reviews note antioxidant effects only.
Read the Pine Pollen report →Cardiovascular is the one place GHRP-6 has a distinct research story, but it is preclinical. A second receptor, CD36, mediates a cytoprotective heart effect, per Bodart 2002, and GHRP-6 reduced oxidant damage…
Read the GHRP-6 report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Tirzepatide, at 6.1, then semaglutide at 6.0, then orforglipron at 5.8 if you want the pill. All three are approved, all three have real trial evidence, and all…
Ca-AKG, urolithin A and MOTS-c tie at 6.5, and only the first two are things you can legally buy. SS-31 follows at 6.0. The bottom three score low…
BPC-157 wins for acute tendon or muscle injuries, gut healing, and cost-sensitive use. TB-500 wins for cardiac tissue repair and systemic post-surgical recovery. Both score 7.3 in the…
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
No. Omega-3 scores 6.8 and C15:0 4.9, and the evidence gap is larger than the score gap. C15:0 has two small human trials. Omega-3 has outcome trials, prescription…
Tesamorelin, unless price is the only thing deciding. It is FDA-approved for visceral fat with Phase 3 trials behind it, while CJC-1295 is a gray-market research peptide whose…
Different jobs, same shelf. Quercetin scores 6.8 and curcumin 6.5, which decides nothing. Curcumin wins joints, inflammatory markers, gut and mood. Quercetin wins allergies, blood pressure, uric acid…
No, and the reason is mechanical. A drink raises blood ketones in an hour. It does not lower insulin, deplete glycogen or shift fuel use. The diet scores…
Magnesium glycinate is magnesium bound to glycine, so if you take it you already take both. That kills the question for sleep. The real decision: magnesium scores higher…
Spermidine scores 7.6 and urolithin A 6.5, and they clean up different messes. Spermidine drives broad autophagy: autophagy 8.0, cardiovascular 7.8, longevity 7.5. Urolithin A drives selective mitophagy…
Sulforaphane scores 6.8 and glutathione 6.2, and both have a delivery problem. Sulforaphane needs active myrosinase or you absorb half as much. Plain oral glutathione barely raises blood…
Magnesium, if the problem is sleep quality. It scores 8.7 against melatonin's 8.2 and leads sleep-quality 8.6 to 7.1, with a larger measured cut to sleep latency. Melatonin…
Taurine, at 9.0 out of 10 for heart health. Taurine earns 9.0/10 for cardiovascular because Guan 2020 reports Confirmed meta-analysis on obesity, BP, and lipid outcomes; supports cardiometabolic breadth.
Of the top-scoring options, Taurine is the least expensive at about $3 a month, scoring 9.0 out of 10 for heart health.
73 of the 120 interventions evaluated for heart health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
